Alkylated imino sugars exhibiting glucosidase inhibition and their method of use
Pharmaceutical compositions of the invention comprise alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include Viral hemorrhagic fevers, and any other diseases involving glucosidase activity.
1. A method of treating a flavivirus infection said method comprising administering to a subject an effective amount of at least one compound having formula (III):
including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:
R 1 at each occurrence is independently selected from the group consisting of hydrogen and COR 4 ;
R 5 is selected from a group consisting of optionally substituted C 1-6 alkyl, optionally substituted branched C 1-6 alkyl, optionally substituted cyclic C 3-8 alkyl, optionally substituted C 5 -C 10 bicylcoalkyl, optionally substituted aryl which may be substituted by 0-5 moieties, OR 5 , and NHR 6 ;
R 3 is selected from a group consisting of optionally substituted C 1-6 alkyl, optionally substituted branched C 1-6 alkyl, optionally substituted cyclic C 3-8 alkyl, 1-adamantyl, 2-adamantyl, optionally substituted C 5 -C 10 bicylcoalkyl, and optionally substituted aryl which may be substituted by 0-5 moieties;
R 3 and R 5 are taken together with the atom to which they are bound to form an optionally substituted ring having 5 ring atoms;
R 3 and R 5 are taken together with the atom to which they are bound to form an optibonally substituted ring having 5 ring atoms;
R 3 and R 5 are taken together with the atom to which they are bound to form
R 3 and R 5 are taken together with the atom to which they are bound to form
R 4 at each occurrence is independently selected from the group consisting of optionally substituted C 1-6 alkyl and optionally substituted branched C 1-6 alkyl;
R 5 is selected from a group consisting of an optionally substituted C 1-6 alkyl, optionally substituted branched C 1-6 alkyl, optionally substituted cyclic C 3-8 alkyl, optionally substituted C 5 -C 10 bicyicoalkyl, optionally substituted aryl which may be substituted by 0-5 moieties;
R 6 is selected from a group consisting of hydrogen, an optionally substituted C 1-6 alkyl, optionally substituted branched C 1-6 alkyl, optionally substituted cyclic C 3-8 alkyl, optionally substituted C 5-10 bicylcoalkyl, optionally substituted aryl which may be substituted by 0-5 moieties; and
R 7a , R 7b ,R 7c and R 7d are each selected from a group consisting of hydrogen, halogen, optionally substituted C 1-6 alkyl, optionally substituted branched C 1-6 alkyl, and optionally substituted C 1-6 alkoxy.
2. The method of claim 1 , wherein the at least one compound is administered in a composition further comprising at least one excipient.
3. The method of claim 1 , wherein the flavivirus is bovine viral diarrhea virus (BVDV).
4. The method of claim 3 , wherein the flavivirus is dengue fever virus (DV).
5. The method of claim 1 , wherein the flavivirus is West Nile virus (WNV).